Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14

– Conference Call and Webcast to Follow at 1:30 p.m. PST/4:30 p.m. EST -

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to be submitted to ir@tivichealth.com by November 11.

Conference Call Details:

Toll Free: 877-545-0523

International: 973-528-0016

Access Code: 507355

Webcast Link

https://www.webcaster4.com/Webcast/Page/2865/51524

About Tivic Health

Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s technology platforms leverage stimulation of the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  198.79
-0.81 (-0.41%)
AAPL  255.78
-5.95 (-2.27%)
AMD  207.32
+1.38 (0.67%)
BAC  52.55
+0.03 (0.06%)
GOOG  306.02
-3.35 (-1.08%)
META  639.77
-10.04 (-1.55%)
MSFT  401.32
-0.52 (-0.13%)
NVDA  182.81
-4.13 (-2.21%)
ORCL  160.14
+3.66 (2.34%)
TSLA  417.44
+0.37 (0.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.